BTAI (BioXcel Therapeutics) Moat Score: 3/10 (As of Jul. 05, 2026)


BTAI BioXcel Therapeutics Inc BTAI
8 GF Score
Price $1.38
GF Value $0.67
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is BioXcel Therapeutics Moat Score?

BioXcel Therapeutics BTAI 8 Moat Score is 3 as of Jul. 05, 2026. GuruFocus rates BTAI with a GF Score™ of 8/100 and a GF Value™ of $0.67 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,030 Drug Manufacturers companies, BioXcel Therapeutics ranks better than 86.12% on this metric.

BioXcel Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

BioXcel Therapeutics has No Moat: BTAI is in a competitive biotech sector with limited market share and lacks significant intellectual property or regulatory advantages, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BioXcel Therapeutics might have No Moat - Very weak/transient advantages.

BioXcel Therapeutics  (NAS:BTAI) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BioXcel Therapeutics Moat Score Related Terms

BTAI vs IXHL, SCYX, INIS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioXcel Therapeutics Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's Moat Score falls into.


BTAI
8GF Score
BioXcel Therapeutics Inc BTAI
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
BioXcel Therapeutics (BTAI) has a Moat Score of 3 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, BioXcel Therapeutics ranks #143 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is BioXcel Therapeutics' Moat Score too high?
BioXcel Therapeutics' current Moat Score is 3. Based on the distribution chart, BioXcel Therapeutics ranks #143 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioXcel Therapeutics has a GF Score™ of 8/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Moat Score compare to IXHL and SCYX?
According to the Drug Manufacturers industry distribution chart, BioXcel Therapeutics ranks #143 out of 1030 companies for Moat Score. This places BioXcel Therapeutics in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. BioXcel Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $1.38 — trading 106% above its estimated fair value. The current Moat Score is 3. BioXcel Therapeutics' overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current Moat Score is 3 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioXcel Therapeutics (BTAI) Overvalued in 2026?

Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued. The current stock price of $1.38 is trading 106% above its estimated GF Value™ of $0.67. GuruFocus considers BioXcel Therapeutics to be Significantly Overvalued.

Key valuation signals for BTAI:

  • Moat Score: 3
  • GF Value™: $0.67 vs. price of $1.38 (106% above fair value)
  • GF Score™: 8/100 with 6 warning signs

No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioXcel Therapeutics Business Description

Other Exchanges BX20:Germany
Address 555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
8GF Score

Get the complete analysis for BTAI

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.38
Price
$0.67
GF Value